PLoS ONE (Jan 2017)

Plasma metabolomics reveals a diagnostic metabolic fingerprint for mitochondrial aconitase (ACO2) deficiency.

  • Lucia Abela,
  • Ronen Spiegel,
  • Lisa M Crowther,
  • Andrea Klein,
  • Katharina Steindl,
  • Sorina Mihaela Papuc,
  • Pascal Joset,
  • Yoav Zehavi,
  • Anita Rauch,
  • Barbara Plecko,
  • Thomas Luke Simmons

DOI
https://doi.org/10.1371/journal.pone.0176363
Journal volume & issue
Vol. 12, no. 5
p. e0176363

Abstract

Read online

Mitochondrial respiratory chain dysfunction has been identified in a number of neurodegenerative disorders. Infantile cerebellar-retinal degeneration associated with mutations in the mitochondrial aconitase 2 gene (ACO2) has been recently described as a neurodegenerative disease of autosomal recessive inheritance. To date there is no biomarker for ACO2 deficiency and diagnosis relies on genetic analysis. Here we report global metabolic profiling in eight patients with ACO2 deficiency. Using an LC-MS-based metabolomics platform we have identified several metabolites with affected plasma concentrations including the tricarboxylic acid cycle metabolites cis-aconitate, isocitrate and alpha-ketoglutarate, as well as phosphoenolpyruvate and hydroxybutyrate. Taken together we report a diagnostic metabolic fingerprint for mitochondrial aconitase 2 deficiency.